Oxurion NV — Director's Dealing 2024

Dec 9, 2024

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Leuven, BELGIUM – December 9, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received a transparency notification on December 6, 2024, from Atlas Special Opportunities, LLC indicating that as of December 5, 2024, it held 564,856 shares of the then outstanding 2,567,406 shares, and therefore crossed above the threshold (20%) by virtue of the purchase of voting securities.

Oxurion received a transparency notification on December 6, 2024, from Atlas Special Opportunities, LLC indicating that as of December 6, 2024, it held 496,161 shares of the then outstanding 2,567,406 shares, and therefore crossed under the threshold (20%) by virtue of the sale of voting securities.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com

________

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA MARKETS AUTHORITY	FINANCIAL SERVICES AND	Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer
	Name OXURION
Identification number 0881-620-924
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name	Address (for legal entities)
	Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name	Address (for legal entities)
	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
		05/12/2024 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		20
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
	2,567,406
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights	% of voting rights

Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to securitie
Special Opportunities LLC	97.098	564.856		22.00%
	TOTAL	564.856	0	22.00%	0.00%

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
	TOTAL			0	0.00%
P	The totals will be updated once you have clicked on
	TOTAL (A & B)				# of voting rights % of voting rights

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

CALCULATE

564,856

22.00%

12) In case of proxy voting for only one GM

Holder	will cease to hold / will hold again	voting rights as of

13) Additional information

On 2 December 2024, Not section 2024, Nas Special Opportunities LC sol 97,09 shares n Cruinon NV, as a result of which its stare of 0.0%,
denominator = 2,567,406).
On 3 December 2024 (with settener t cle on 5 Decar Oportunities LC aggures 564,656 stars in Ourino N. as a result of Mich its stares of of Mich its stares of of 54,65 shares
22.00%, denominator = 2,567,406).

Done at New York
On		05/12/2024 (DD/MM/YYYY)
	Name & capacity Patrick Vance, Proxyholder	-Signed by: Signature -948047899054428	Patvice Varie

For security reasons, the unsigned form in xlsx format should be
transmitted to trp.fin@fsma.be. You can do this manually
OR if you have MS Outlook at your disposal via the "

In addition, a signed copy in PDE format should also be
transmitted.

ANNEX 2

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer
ldentification number 0881-620-924	Name OXURION
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name	Address (for legal entities)
	Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name	Address (for legal entities)
ar	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
		06/12/2024 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		20
		If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
		2,567,406
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification	After the transaction
	# of votina riahts	# of voting rights % of voting rights

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	564.856	496.161		19.33%
	TOTAL	496.161	0	19.33%	0.00%

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
TOTAL					0.00%
P	The totals will be updated once you have clicked on

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	496,161	19.33%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

12) In case of proxy voting for only one GM

			100/MM/1000
Holder	will cease to hold / will hold again	voting rights as of

13) Additional information

Ch 4 December 2024 (with sellenent date on 6 December 2024), Atlas Special Opportunities L.C sol 68,65 shares in Ourion NV, as a result of virith is sharending deseased of 40

Done at New York
On	06/12/2024 (DD/MMYYYYY)
Name & capacity Patrick Vance, Proxyholder	- Samed by Patrick Varie Signature

For security reasons, the unsigned form in xlsx format should be
transmitted to trp.fin@fsma.be. You can do this manually
OR if you have MS Outlook at your disposal via th

In addition, a signed copy in PDE format should also be
transmitted.